Conserved B-cell epitope peptide of Mycoplasma pneumoniae P1 protein and its application in the diagnosis of Mycoplasma pneumoniae antibody

By utilizing the conserved B-cell epitope peptide QV11 on the surface adhesin protein P1 of Mycoplasma pneumoniae and expressing it through Peg pili, a direct agglutination assay mediated by QV11 epitope and antibody was established. This solved the specificity and sensitivity problems of traditional detection methods, enabling rapid and accurate detection of MP antibodies, which is suitable for clinical diagnosis and public health monitoring.

CN123106853APending Publication Date: 2026-11-17YANGZHOU UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611573819.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-12
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing traditional serological testing methods have technical bottlenecks in terms of specificity and sensitivity, making it difficult to meet the needs of clinical diagnosis and public health prevention and control. They also cannot effectively exclude differences in the physicochemical properties of samples or non-specific reactions, which limits the accurate detection of Mycoplasma pneumoniae infection and large-scale population screening.

Method used

By using the conserved B-cell epitope peptide QV11 on the surface adhesin protein P1 of Mycoplasma pneumoniae, and expressing it through Peg pili, a direct agglutination assay mediated by QV11 epitope and antibody was established to achieve the detection of MP antibodies with high specificity and sensitivity.

Benefits of technology

It enables rapid and accurate detection of MP antibodies within 2 minutes, avoids cross-reaction, has the potential for clinical application, and is suitable for clinical diagnosis and treatment as well as public health monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106853A_ABST
    Figure CN123106853A_ABST
Patent Text Reader

Abstract

This invention discloses a conserved B-cell epitope peptide of Mycoplasma pneumoniae P1 protein and its application in the diagnosis of Mycoplasma pneumoniae antibodies. The amino acid sequence of the conserved B-cell epitope peptide of Mycoplasma pneumoniae P1 protein is shown in SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7, or SEQ ID NO.8. The conserved B-cell epitope peptide can be functionally expressed on the surface of inert S9H bacterial cells. A direct agglutination assay mediated by the QV11 epitope and antibody, based on the expression on the S9H bacterial cell surface, shows that QV11 specifically recognizes Mycoplasma pneumoniae infection antibodies and exhibits no cross-reactivity with serum antibodies against other infectious diseases. The clinical sample test results showed a concordance rate of up to 94% with chemiluminescence immunoassay (CLIA). This diagnostic method is highly specific, easy to operate, and provides intuitive results, making it a promising technical means for the visual and precise on-site diagnosis of Mycoplasma pneumoniae infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical and immunodiagnostic detection technology, specifically relating to the conserved B-cell epitope peptide of Mycoplasma pneumoniae adhesin P1 protein and its application in the diagnosis of Mycoplasma pneumoniae antibodies. In particular, it relates to the detection of Mycoplasma pneumoniae infection by utilizing the characteristic sequence of the conserved B-cell epitope peptide QDTQPNNNVQV (QV11) on the surface adhesin protein P1 of Mycoplasma pneumoniae and the QV11 epitope-antibody directly mediated agglutination assay, which can accurately diagnose Mycoplasma pneumoniae infection and evaluate its potential applications in vaccine assessment. Background Technology

[0002] Mycoplasma pneumoniae (MP) is a major pathogen of community-acquired pneumonia (CAP), accounting for approximately 5%-10% of CAP cases. It is particularly common in children and adolescents, but elderly patients are also highly susceptible. This pathogen can cause periodic epidemic outbreaks in neighboring populations and, in addition to primary respiratory infections, can lead to multi-system extrapulmonary complications, seriously threatening public health. Because Mycoplasma pneumoniae lacks a cell wall structure, it is naturally insensitive to commonly used β-lactam and sulfonamide antibiotics. The clinical symptoms and imaging manifestations of pneumonia caused by it are highly similar to those of other bacterial and viral pneumonias, lacking specific diagnostic criteria, making empirical clinical medication prone to treatment errors. In children, adolescents, and the elderly with weakened immune systems, MP infection can not only cause severe respiratory damage such as necrotizing pneumonia and respiratory failure, but also induce serious extrapulmonary complications such as encephalitis, myocarditis, and immune hemolytic anemia through immune-mediated mechanisms, significantly prolonging the course of the disease and increasing mortality. Meanwhile, Mycoplasma pneumoniae infection exhibits distinct periodicity, with regional outbreaks occurring globally every 3-7 years. Large-scale outbreaks are highly likely to occur in enclosed, crowded places such as schools, kindergartens, and nursing homes. Recent multi-center surveillance data in my country shows that Mycoplasma pneumoniae accounts for 10%-30% of childhood community-acquired pneumonia (CAP) cases, even exceeding 40% in peak years. Furthermore, the prevalence of drug-resistant strains is continuously increasing, posing a significant public health challenge. Rapid and accurate pathogen detection is a core prerequisite for supporting precise clinical diagnosis and treatment, guiding the rational use of targeted antibiotics, curbing the spread of drug-resistant strains, improving the public health surveillance system, and achieving early warning of outbreaks.

[0003] However, existing traditional serological testing methods still face significant technical bottlenecks in terms of specificity and sensitivity, making it difficult to meet the dual needs of clinical diagnosis and public health control. On the one hand, intact protein antigens typically contain a large number of redundant epitopes, which can easily lead to increased background signals and non-specific reactions during detection, affecting the accuracy of result interpretation. On the other hand, detection methods based on solid-phase carrier-coated protein antigens have limited coating area, resulting in limited antigen concentration and molecule count per unit reaction system, thus restricting further improvements in detection sensitivity. Furthermore, these methods usually only include systemic controls, lacking intrinsic controls for single samples, making it difficult to effectively eliminate interference from differences in sample physicochemical properties or non-specific reactions. This limits their precise application in clinical settings and cannot adequately support large-scale epidemiological screening of populations.

[0004] Existing research on pathogenic mechanisms indicates that the key to Mycoplasma pneumoniae infection begins with its adhesion and colonization of the host's respiratory epithelial cells. Antibody responses to adhesion-associated antigens are typically characterized by early onset and high specificity, making them ideal targets for serological diagnosis. Currently identified major adhesion structures in Mycoplasma pneumoniae include transmembrane proteins P1 (169 kDa) and P30 (30 kDa), which are highly aggregated in the adhesion organelle region at one end of the mycoplasma. These proteins play a central role in pathogen adhesion, colonization, and pathogenesis, and are currently promising candidate antigens for immunological detection of Mycoplasma pneumoniae. Immunological detection of these adhesion-associated antigens has significant diagnostic value and development potential. Summary of the Invention

[0005] Purpose of the invention: The technical problem to be solved by the present invention is to provide a conserved B-cell epitope peptide on the surface adhesin protein P1 of Mycoplasma pneumoniae.

[0006] Another technical problem that the present invention needs to solve is to provide a polynucleotide encoding the conserved B-cell epitope peptide.

[0007] Another technical problem that the present invention needs to solve is to provide a recombinant polynucleotide containing the said polynucleotide.

[0008] Another technical problem that the present invention also addresses is to provide an expression cassette, recombinant vector, recombinant cell, or recombinant strain containing the said polynucleotide or the said recombinant polynucleotide.

[0009] Another technical problem to be solved by the present invention is to provide a Mycoplasma pneumoniae-specific antibody detection system containing an expression cassette, a recombinant vector, recombinant cells or recombinant strains.

[0010] Another technical problem that this invention aims to solve is to provide a method for constructing recombinant vectors or recombinant strains.

[0011] Another technical problem to be solved by the present invention is to provide the application of the conserved B-cell epitope peptide, the polynucleotide, the recombinant polynucleotide, the expression cassette, the recombinant vector, the recombinant cell or recombinant strain, and the detection system in the preparation of Mycoplasma pneumoniae specific antibody detection reagents or kits.

[0012] The final technical problem to be solved by this invention is to provide a reagent or kit for detecting Mycoplasma pneumoniae-specific antibodies.

[0013] Technical solution: In order to solve the above-mentioned technical problems, the first aspect of the present invention provides a conserved B-cell epitope peptide of Mycoplasma pneumoniae P1 protein, wherein the amino acid sequence of the B-cell epitope peptide is shown in SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7 or SEQ ID NO.8. Preferably, the amino acid sequence of the B-cell epitope peptide is QDTQPNNNVQV (SEQ ID NO.7), named QV11.

[0014] A second aspect of the present invention provides a polynucleotide encoding the B-cell epitope peptide, wherein the nucleotide sequence of the polynucleotide is shown in SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11 or SEQ ID NO. 12.

[0015] Preferably, the nucleotide sequence of the polynucleotide is CAGGATACCCAGCCGAACAACAACGTGCAGGTG (SEQ ID NO.11).

[0016] A third aspect of the present invention provides a recombinant polynucleotide, wherein the recombinant polynucleotide is obtained by encoding the nucleotide sequence of the B cell epitope peptide or by inserting the polynucleotide into the gene sequence encoding the PegA subunit of the Peg fimbriae. Preferably, the nucleotide sequence of the recombinant polynucleotide is shown in SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15 or SEQ ID NO. 16. Preferably, the nucleotide sequence of the recombinant polynucleotide is shown in SEQ ID NO. 15.

[0017] A fourth aspect of the present invention provides a recombinant fusion protein comprising a cytoskeletal protein and the aforementioned B-cell epitope peptide inserted therein. Preferably, the amino acid sequence of the recombinant protein is shown in SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19 or SEQ ID NO.20.

[0018] A fifth aspect of the present invention provides an expression cassette, a recombinant vector, a recombinant cell, or a recombinant bacterial strain containing the aforementioned polynucleotide or the aforementioned recombinant polynucleotide. The recombinant bacterial strain is obtained by introducing the recombinant vector into a vector bacterium.

[0019] The sixth aspect of this invention provides a method for constructing the recombinant vector, comprising the following steps:

[0020] (1) Obtaining the nucleic acid DNA sequence of the conserved B-cell epitope peptide of Mycoplasma pneumoniae adhesin protein P1, wherein the DNA sequence of the nucleic acid molecule is shown in SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11 or SEQ ID NO.12; preferably, the DNA sequence of the nucleic acid molecule is CAGGATACCCAGCCGAACAACAACGTGCAGGTG (SEQ ID NO.11).

[0021] (2) The DNA sequence obtained in step (1) is introduced into the PegA subunit encoding gene sequence of Peg fimbriae to construct a recombinant polynucleotide; the sequence of the recombinant polynucleotide is shown in SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15 or SEQ ID NO.16; preferably, the sequence of the recombinant polynucleotide is shown in SEQ ID NO.15.

[0022] (3) The recombinant polynucleotide obtained in step (2) is ligated into the vector to construct the recombinant vector.

[0023] The seventh aspect of the present invention provides a method for constructing the recombinant strain, the method comprising transforming the recombinant vector into a vector bacterium to obtain the strain.

[0024] The eighth aspect of the present invention provides a Mycoplasma pneumoniae antibody detection system, the Mycoplasma pneumoniae antibody detection system comprising the aforementioned expression cassette, recombinant vector, recombinant cells or recombinant strain.

[0025] The application of the B-cell epitope peptide, the polynucleotide, the recombinant polynucleotide, the recombinant fusion protein, the expression cassette, the recombinant vector, the recombinant cell, the recombinant strain, or the detection system in Mycoplasma pneumoniae antibody detection reagents or kits.

[0026] The ninth aspect of the present invention provides a detection reagent or kit for Mycoplasma pneumoniae antibodies, the reagent or kit comprising the B-cell epitope peptide, the polynucleotide, the recombinant polynucleotide, the recombinant fusion protein, the expression cassette, the recombinant vector, the recombinant cell, the recombinant strain, or the detection system.

[0027] Beneficial Effects: Compared with existing detection technologies, this invention has the following significant advantages: The MPP1 B-cell conserved epitope peptide QV11 described in this invention originates from the conserved antigenic epitope determinant domain of MPP1. By utilizing the pili presentation of the conserved B-cell epitope peptide QV11, a direct agglutination assay based on the QV11 epitope-antibody mediated reaction was established to detect MP antibodies in MP-infected individuals. The conserved B-cell epitope peptide QV11 presented on the bacterial surface specifically recognizes and binds to MP antibodies, thereby achieving specific, convenient, and rapid detection of MP antibodies. The Mycoplasma pneumoniae specific antibody detection system described herein only specifically binds to MP antibodies, without cross-reaction or non-specific reactions with antibodies against other infectious disease pathogens. MP infection can be detected within 2 minutes using the method of this invention. Given the high specificity, high sensitivity, and simple operation of this invention, it is easy to promote and apply in clinical practice and is expected to become an important technical means for detecting MP infection. Attached Figure Description

[0028] Figure 1 Infographic of 44 protein sequences used for conservation analysis of Mycoplasma pneumoniae P1;

[0029] Figure 2 This image shows the conservation comparison results of 44 Mycoplasma pneumoniae P1 proteins. The top horizontal axis (1-44) corresponds to the amino acid sequences on the right vertical axis (1-44). The percentage of the intersection of the horizontal and vertical axes represents the identity (conservation) between two amino acid sequences. The bottom left shows Divergence: sequence differentiation distance (difference degree). The larger the number, the greater the base difference in the nucleic acid sequence, and the more different base sites there are (0.1 indicates a proportion of 0.1%, meaning one difference out of 1000 bases).

[0030] Figure 3 A diagram showing the sequence information of 338 Mycoplasma pneumoniae P1 proteins;

[0031] Figure 4 This is a graph showing the conservation results for predicted epitope peptides. The horizontal axis represents the number of amino acids; if a column shows only a single amino acid, it indicates that the site is 100% conserved. The vertical axis has a maximum value of 1, indicating 100% conservation. The height percentage of each letter in each column indicates the conservation of the corresponding amino acid at that site.

[0032] Figure 5 The diagram shows the construction pattern of the recombinant vector pBR-PegA-ST11 / TT11 / QV11 / AG11, in which the four B-cell epitope peptides on the MP P1 protein are inserted into PegA. The red "epitope" indicates the insertion site of the epitope peptide.

[0033] Figure 6This image shows the results of functional validation of MP P1 protein candidate B cell epitopes; white arrows indicate specific agglutinated particles.

[0034] Figure 7 The graph shows the agglutination results of the MP antibody specific detection system S9H-pBR-PegA-QV11 and the control system S9H-Peg with MP antibody-positive serum, other pathogen antibody-positive serum, or negative serum, respectively. A: Agglutination results of MP antibody-positive serum, with white arrows indicating agglutinated particles; B: No agglutination in human respiratory syncytial virus (HRSV) antibody-positive serum; C: No agglutination in porcine mycoplasma pneumoniae antibody-positive serum; D: No agglutination in porcine mycoplasma rhinosum antibody-positive serum; E: No agglutination in SPF porcine serum; F: No agglutination in porcine pseudorabies virus antibody-positive serum; G: No agglutination in porcine reproductive and respiratory syndrome virus antibody-positive serum; H: No agglutination in porcine Lawsonia intracellularis antibody-positive serum; I: No agglutination in serum from volunteers infected with Helicobacter pylori; J: No agglutination in serum from volunteers from volunteers with known clinical positive results for Mycobacterium tuberculosis. Detailed Implementation

[0035] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below. It should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention. Test methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or according to the conditions recommended by the respective manufacturers.

[0036] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the present invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, apparatus, and materials used in the embodiments, based on the knowledge of the prior art possessed by one of ordinary skill in the art and the description of this invention, any prior art methods, apparatus, and materials similar to or equivalent to those described, apparatus, and materials in the embodiments of this invention may be used to implement the present invention.

[0037] Example 1: Prediction of conserved B-cell epitope peptides of Mycoplasma pneumoniae adhesin protein P1

[0038] The P1 protein sequence information of Mycoplasma pneumoniae was retrieved from the NCBI (https: / / www.ncbi.nlm.nih.gov / ) Protein database. Forty-four Mycoplasma pneumoniae P1 protein sequences were selected, including strains reported from China, the United States, the United Kingdom, France, Germany, South Korea, Japan, Egypt, Kenya, Guatemala, the Netherlands, and Denmark. Figure 1 The amino acid sequences of the 44 Mycoplasma pneumoniae strains were compared and analyzed using bioinformatics software (DNASTAR Lasergene MegAlign 7.0.0). The amino acid sequence conservation of the Mycoplasma pneumoniae P1 protein was 92.3%. Figure 2 (See the red rectangle for selection).

[0039] The key domain (1182-1629 amino acids) of the C-terminus of MP S4 P1 protein (accession number: WP_084253829.1) adhering to ciliated epithelial cells was analyzed using the online B-cell epitope peptide prediction software BepiPred-3.0 (https: / / services.healthtech.dtu.dk / services / BepiPred-3.0 / ) (parameter settings: confidence (top 20%); threshold (0.2); linear epitope prediction mode). The epitope peptide length was limited to 11 amino acids. The results showed that there were 8 B-cell linear epitope peptides that met the requirements in amino acids 1182-1629 of MP P1 protein (Table 1). The conservation of the above B-cell epitope peptides was analyzed using MEGA 12 bioinformatics software. Among the 338 P1 protein sequences in the NCBI Protein database (…),… Figure 3 (Protein sequence data obtained up to January 19, 2026). Epitope peptides 1-7 as shown in Table 1 were selected for further analysis. Epitope peptides 3, 5, 6, 7, and 8 are completely conserved, and the epitope sequences cover all strains. Figure 4 ).

[0040] To ensure that the selected conserved B-cell epitope peptides of MP-P1 are specific to other respiratory pathogens and do not cross-react with serum antibodies against other pathogens, epitope peptides 3, 5, 6, 7, and 8 were sequence-aligned in the NCBI database using the Basic Local Alignment Search Tool (blastp, default parameters). The results showed that epitope peptide 6 (amino acid sequence: GEGQTADTGPQ) has amino acid sequences that are repeated with the fusion inhibitory domain protein [rhizobium] and the putative protein [Pseudomonas bacteria]. This indicates that these three proteins can stimulate the body to produce antibodies against this epitope, which may lead to false positive results due to antibody cross-reactivity.

[0041] Table 1. Prediction results of B-cell epitope peptides of MPP1

[0042]

[0043] Example 2: Construction and functional expression verification of recombinant strains expressing conserved B-cell epitope peptides 3, 5, 7, and 8 of MPP1.

[0044] Nucleic acid molecules containing MP P1 conserved B-cell epitope peptides 3, 5, 7, and 8 (Table 2) were introduced into the coding gene sequence of the PegA subunit of Salmonella Peg fimbriae, and then ligated into the pBR322-Peg recombinant plasmid (pBR322-Peg was previously constructed and preserved in the laboratory, derived from the Chinese invention patent with patent number ZL202211488632.8, entitled "Target Antigen of Novel Coronavirus Receptor Binding Domain B-cell Epitope and Its Presentation and Application in Peg Filiforme") to construct the recombinant vector rpBR322-Peg. Figure 5 The recombinant vector was then transferred into an inert vector bacterium (S9H inert vector bacterium is derived from Chinese invention patent No. ZL202010427735.8, entitled "A Universal Inert Vector Salmonella and Its Potential Applications") to verify the functional B-cell epitope peptides displayed on the surface of the inert vector bacterium.

[0045] Table 2. Nucleotide information of MP P1 protein B-cell epitope peptides

[0046]

[0047] The specific implementation procedure is as follows: The nucleic acid molecules of epitope peptides 3, 5, 7, and 8 were respectively replaced with CTTGATGGTATTCAGGTGAAACCGGATGAGGCG in the PegA gene sequence. The resulting recombinant gene DNA fragments were named PegA-ST11, PegA-TT11, PegA-QV11, and PegA-AG11, respectively. The nucleotide sequences of the recombinant gene DNA fragments are shown in SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15, and SEQ ID NO.16. The recombinant genes PegA-ST11 (550bp), PegA-TT11 (550bp), PegA-QV11 (550bp), and PegA-AG11 (550bp) were synthesized by Nanjing Qingke Biotechnology Co., Ltd.

[0048] Using the synthesized DNA fragments as templates, PCR amplification was performed using upstream and downstream primers, respectively. Upstream primer PegA-up: 5'-CGC GCTAGC ATGAAACGTTCACTTATTGCTGCT-3', downstream primer PegA-down: 5'-GC GCTNAGCCGCCAAAAAACGATTGTT-3', where the underscores represent the Nhe I and Blp I restriction enzyme sites, synthesized by Nanjing Qingke Biotechnology Co., Ltd. The amplification system consisted of: 2 μL of pfu high-fidelity DNA polymerase (Beijing TransGen Biotech Co., Ltd., 2.5 U / μL), 10 μL of 5×pfu DNA polymerase buffer, 5 μL of dNTPs, 2 μL each of forward and reverse primers (10 mM), 2 μL of recombinant gene DNA fragment (1 ng / μL), and 27 μL of ultrapure water. After thoroughly mixing the above system, PCR amplification was performed using a Bio-Red thermal cycler. The program was as follows: pre-denaturation at 94 ℃ for 5 min; denaturation at 94 ℃ for 30 s, annealing at 52 ℃ for 30 s, and extension at 72 ℃ for 30 s, for a further amplification at 72 ℃ for 10 min. After amplification, the temperature was lowered to 12 ℃. Prepare a 1.5% agarose gel, electrophoresis at 100 V for 50 min, stain with ethidium bromide and image under a UV imager. Four PCR amplification products (568 bp) were recovered using a universal DNA purification kit (Tiangen Biotech (Beijing) Co., Ltd.).

[0049] Four PCR amplification products and the pBR322-Peg plasmid were double-digested with Nhe I and Blp I restriction endonucleases (NEB), respectively. Then, the four linear DNA fragments were ligated overnight at 16 °C using T4 DNA ligase (NEB). The ligation system consisted of 2 μL of pBR322-Peg plasmid, 6 μL of DNA fragments, 1 μL of T4 DNA ligase (NEB, 400 U / μL), 2.5 μL of 10×T4 DNA Ligase Reaction Buffer, and 13.5 μL of ddH2O, for a total of 25 μL. The ligation products were transformed into DH5α competent cells (prepared and preserved in our laboratory) the next day, and resistance selection was performed by plating on solid medium containing 100 μg / mL ampicillin. Single colonies from the plates were inoculated into LB broth containing 100 μg / mL ampicillin and grown to the plateau phase. The plasmids were recovered and identified by double digestion with Nhe I and Blp I restriction endonucleases. The results showed that the Nhe I and Blp I double digestion products of the recombinant vector contained an 8493 bp linear vector and a 557 bp linear DNA fragment, consistent with the expected size, indicating successful construction of four B-cell epitope peptide presentation recombinant vectors, named pBR-PegA-ST11, pBR-PegA-TT11, pBR-PegA-QV11, and pBR-PegA-AG11. pBR-PegA-ST11, pBR-PegA-TT11, pBR-PegA-QV11, and pBR-PegA-AG11 were transformed into S9H competent cells, and resistance selection was performed by plating on solid medium containing 100 μg / mL ampicillin. Finally, recombinant bacteria expressing B-cell epitope peptides on their surface were screened and named S9H-pBR-PegA-ST11, S9H-pBR-PegA-TT11, S9H-pBR-PegA-QV11, and S9H-pBR-PegA-AG11, respectively.

[0050] Recombinant bacteria S9H-pBR-PegA-ST11, S9H-pBR-PegA-TT11, S9H-pBR-PegA-QV11, and S9H-pBR-PegA-AG11 were cultured in LB broth containing 100 μg / mL ampicillin until the plateau phase. After centrifugation at 4000 rpm for 5 min, the supernatant was discarded, and the bacteria were resuspended in an equal volume of sterile physiological saline. This process was repeated twice by centrifugation to prepare bacterial suspensions. The bacterial suspensions of recombinant bacteria S9H-pBR-PegA-ST11, S9H-pBR-PegA-TT11, S9H-pBR-PegA-QV11, and S9H-pBR-PegA-AG11 (final concentration of 1×10⁻⁶) were then cultured to a final concentration of 1×10⁻⁶.10 CFU / mL) and MP antibody-negative serum (10 samples, provided by Subei People's Hospital), Salmonella Peg antibody-positive mouse serum (10 samples, prepared and preserved by this experiment), and MP antibody-positive serum (10 samples, from Yangzhou Maternal and Child Health Hospital) were used to perform glass plate agglutination tests. S9H engineered bacteria containing only pBR-Peg (final concentration 1×10⁻⁶) were also used. 10 A bacterial suspension containing CFU / mL (S9H engineered bacteria containing pBR-Peg, derived from Chinese invention patent ZL202211488632.8, Target antigen of the novel coronavirus receptor-binding domain B-cell epitope and its expression and application in Peg fimbriae) was used as a negative control. The results are shown in Table 3. None of the bacterial suspensions of the five recombinant strains reacted with Mycoplasma pneumoniae antibody-negative serum. All strains agglutinated with Peg antibody-positive mouse serum, confirming that the inert vector S9H successfully displayed immunologically active functional Peg fimbriae on its surface. Based on this, the recognition ability of each strain on Mycoplasma pneumoniae antibody-positive serum was further evaluated, and the results are as follows: Figure 6 As shown, three strains, S9H-pBR-PegA-ST11, S9H-pBR-PegA-TT11, S9H-pBR-PegA-QV11, and S9H-pBR-PegA-AG11, exhibited positive agglutination reactions. Among them, S9H-pBR-PegA-QV11 showed the strongest reaction with large agglutinated particles and a clear background; while S9H-pBR-PegA-ST11, S9H-pBR-PegA-TT11, and S9H-pBR-PegA-AG11 showed only a small number of agglutinated particles, and the agglutination disappeared upon dilution, indicating a weaker reaction. The control strain S9H-Peg (showing only Peg pili) did not agglutinate, further demonstrating that the agglutination reaction originates from the binding of specific epitope peptides displayed on the surface of the recombinant strain to Mycoplasma pneumoniae antibodies. In summary, this invention successfully constructed a functional Peg fimbriae display system and screened the S9H-pBR-PegA-QV11 strain, which simultaneously displays Peg fimbriae and QV11 epitope peptides on its surface, exhibiting excellent antigen presentation performance and the ability to specifically recognize MP antibodies. Combined with the S9H-Peg negative control, this strain can be used to establish a highly specific MP antibody detection method with clear background, laying the foundation for the development of subsequent diagnostic technologies.

[0051] Table 3. Validation results of functional expression of recombinant strains of MPP1 protein B-cell conserved epitope peptide.

[0052]

[0053] Note: "-" indicates a negative agglutination reaction (no agglutinated particles, turbid background), and all samples show 100% non-agglutination; "+++" indicates a positive agglutination reaction (large agglutinated particles, clear background), and all samples show 100% agglutination; "+" indicates a weakly positive agglutination reaction (few agglutinated particles, which disappear after serum is diluted by half).

[0054] Example 3: Cross-reactivity test and specificity evaluation of the MP antibody specific detection system

[0055] Functional validation of the S9H-pBR-PegA-QV11 recombinant strain, which expresses the MP functionally conserved B-cell epitope peptide QV11 on the surface of the inert vector S9H, was performed. The cross-reactivity of the MP antibody-specific detection system was tested, and its detection specificity was evaluated. The specific implementation procedure is as follows:

[0056] The control system S9H-pBR-Peg bacterial suspension and S9H-pBR-PegA-QV11 bacterial suspension (both with a final concentration of 1×10⁻⁶) were prepared according to the method described in Example 2. 10 Agglutination tests were performed on serum samples positive for antibodies against different pathogens (CFU / mL) and the sera tested included: 40 serum samples positive for Mycoplasma pneumoniae antibodies (provided by Yangzhou Maternal and Child Health Hospital and Jiangsu Subei People's Hospital), 5 serum samples positive for human respiratory syncytial virus (HRSV) antibodies (provided by Jiangsu Subei People's Hospital), 30 serum samples from volunteers who were known to be positive for Mycobacterium tuberculosis in clinical practice (provided by Yangzhou Third People's Hospital), 10 serum samples from volunteers who were infected with Helicobacter pylori (provided by Wuxi Xishan People's Hospital), and 20 serum samples positive for Mycoplasma pneumoniae immune antibodies in pigs (provided by Taizhou Huaweite Biopharmaceutical Co., Ltd.). The following serum samples were tested: 1 sample of positive serum for Mycoplasma nasalis antibody (provided by Yangzhou Youbang Biopharmaceutical Co., Ltd.), 20 samples of SPF swine serum (provided by the Animal Hospital of Zhejiang A&F University), 5 samples of positive serum for Pseudorabies virus antibody (provided by Zhejiang Meibaolong Biotechnology Co., Ltd.), 5 samples of positive serum for Porcine reproductive and respiratory syndrome virus (PRRSV) antibody (provided by Zhejiang Meibaolong Biotechnology Co., Ltd.), 4 samples of positive serum for L1 antibody (provided by Taizhou Huaweite Biopharmaceutical Co., Ltd.), 2 samples of positive serum for classical swine fever virus antibody (provided by Jilin University), and 6 samples of positive serum for Escherichia coli antibody (prepared and preserved by our laboratory). The test results are shown in Table 4. Agglutination results for some samples are shown in […]. Figure 7 The MP antibody-specific detection system only exhibits a specific agglutination reaction with MP antibody-positive serum and does not cross-react with positive serum from other infectious disease vaccines, indicating that the detection system has good specificity.

[0057] Table 4. Specificity validation results of the MP antibody specificity detection system

[0058]

[0059] Note: "-" indicates a negative agglutination reaction; "+" indicates a positive agglutination reaction.

[0060] Example 4: Comparison of concordance rates between glass plate agglutination test, chemiluminescence assay, and real-time fluorescence PCR detection results

[0061] This invention involved 50 clinical volunteers. Serum samples and pharyngeal swabs were collected simultaneously. Pharyngeal swabs were used for real-time fluorescent PCR nucleic acid detection, while serum samples were tested using the S9H-pBR-PegA-QV11 glass plate agglutination assay and chemiluminescence immunoassay. The chemiluminescence immunoassay was used as a serological reference to evaluate the detection efficacy of the glass plate agglutination antibody.

[0062] Fifty serum and pharyngeal swab samples were collected from clinical volunteers (provided by Yangzhou Maternal and Child Health Hospital and Jiangsu Subei People's Hospital). Of these 50 cases, 42 pharyngeal swabs were positive for nucleic acid, and all showed elevated body temperature upon clinical examination; 8 were negative for nucleic acid, and none presented with fever. Chemiluminescence immunoassay detected 40 positive and 10 negative samples; the glass plate agglutination test detected 41 positive and 9 negative samples (Table 5). The overall positive rates for the three methods were: PCR 84.00% (42 / 50), chemiluminescence immunoassay 80.00% (40 / 50), and glass plate agglutination test 82.00% (41 / 50) (Table 6).

[0063] The diagnostic efficacy of the glass plate agglutination test was evaluated using chemiluminescence immunoassay as a serological reference. The two methods yielded consistent results in 39 positive cases and 8 negative cases, with an overall consistency of 47 samples, resulting in an overall concordance rate of 94.00%. The diagnostic sensitivity (clinical sensitivity) of the glass plate agglutination test was 97.50%, and the specificity was 80.00%. Kappa test analysis showed a Kappa value of 0.805, indicating good consistency between the glass plate agglutination test and the chemiluminescence immunoassay results.

[0064] Using real-time fluorescent PCR nucleic acid detection from pharyngeal swabs as a reference, the distribution differences between the results of the glass plate agglutination test and the nucleic acid detection were analyzed. Among 42 PCR-positive cases with fever, 40 were positive for glass plate agglutination and 2 were negative; among 8 PCR-negative cases, 1 was positive for glass plate agglutination and 7 were negative. There were 40 cases where glass plate agglutination was consistent with PCR for positive results, 7 cases for negative results, and 47 cases overall consistent, with an overall concordance rate of 94.00%. Using PCR as a reference, the sensitivity of the glass plate agglutination test was 95.24%, the specificity was 87.50%, and the Kappa value was approximately 0.788, indicating good overall consistency between the two methods.

[0065] Table 5. Results of glass plate agglutination test and chemiluminescence assay (four-fold table)

[0066]

[0067] Table 6. Summary of Results and Diagnostic Efficacy of the Three Detection Methods

[0068]

[0069] Note: ᵃ The chemiluminescence assay is used as the serological reference for the stenotic plate agglutination test; ᵇ The pharyngeal swab PCR is used as the reference for the stenotic plate agglutination test. "-" Chemiluminescence and real-time fluorescence PCR are used as references for the stenotic plate agglutination test, and their sensitivity and specificity are not calculated separately.

Claims

1. A conserved B-cell epitope peptide of Mycoplasma pneumoniae P1 protein, characterized in that, The amino acid sequence of the B-cell epitope peptide is shown in SEQ ID NO.3, SEQ ID NO.5, SEQ ID NO.7 or SEQ ID NO.

8.

2. A polynucleotide, characterized in that, The polynucleotide encodes the B-cell epitope peptide of claim 1, and the nucleotide sequence of the polynucleotide is shown in SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11 or SEQ ID NO.

12.

3. A recombinant polynucleotide, characterized in that, The recombinant polynucleotide is obtained by inserting the nucleotide sequence encoding the B cell epitope peptide of claim 1 or the polynucleotide of claim 2 into the Peg fimbriae PegA subunit encoding gene sequence. Preferably, the nucleotide sequence of the recombinant polynucleotide is shown in SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15 or SEQ ID NO.

16.

4. A recombinant fusion protein, characterized in that, The recombinant fusion protein comprises a cytoskeletal protein and an inserted B-cell epitope peptide according to claim 1. Preferably, the amino acid sequence of the recombinant protein is shown in SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19 or SEQ ID NO.

20.

5. An expression cassette, recombinant vector, recombinant cell or recombinant strain, comprising the polynucleotide of claim 2 or the recombinant polynucleotide of claim 3.

6. The method for constructing the recombinant vector according to claim 5, characterized in that, Includes the following steps: (1) Obtaining the nucleic acid DNA sequence of the conserved B-cell epitope peptide of Mycoplasma pneumoniae adhesin protein P1, wherein the DNA sequence of the nucleic acid molecule is shown in SEQ ID NO.9, SEQ ID NO.10, SEQ ID NO.11 or SEQ ID NO.12; (2) The DNA sequence obtained in step (1) is introduced into the PegA subunit encoding gene sequence of Peg fimbriae to construct a recombinant polynucleotide; the sequence of the recombinant polynucleotide is shown in SEQ ID NO.13, SEQ ID NO.14, SEQ ID NO.15 or SEQ ID NO.

16. (3) The recombinant polynucleotide obtained in step (2) is ligated into the vector to construct the recombinant vector.

7. The method for constructing the recombinant strain according to claim 5, characterized in that, The method comprises converting and introducing the recombinant vector of claim 5 into a vector bacterium.

8. A Mycoplasma pneumoniae antibody detection system, characterized in that, The Mycoplasma pneumoniae antibody detection system includes the expression cassette, recombinant vector, recombinant cells, or recombinant strain as described in claim 5.

9. The use of the B-cell epitope peptide of claim 1, the polynucleotide of claim 2, the recombinant polynucleotide of claim 3, the recombinant fusion protein of claim 4, the expression cassette, recombinant vector, recombinant cell, recombinant strain of claim 5, or the detection system of claim 8 in a Mycoplasma pneumoniae antibody detection reagent or kit.

10. A detection reagent or kit for Mycoplasma pneumoniae antibodies, characterized in that, The reagent or kit includes the B-cell epitope peptide of claim 1, the polynucleotide of claim 2, the recombinant polynucleotide of claim 3, the recombinant fusion protein of claim 4, the expression cassette, recombinant vector, recombinant cell, recombinant strain of claim 5, or the detection system of claim 8.

Citation Information

Patent Citations

  • A generalized inert vector Salmonella and its potential applications

    CN111500504B

  • Target antigen of novel coronavirus receptor binding domain B cell epitope as well as expression and application of target antigen in Peg pilus exhibition

    CN116715737A